Last quarter (Q3 2022), Dermapharm Holding SE's total revenue was €263.14M, an increase of 8.54% from the same quarter last year. In Q3, Dermapharm Holding SE's net income was €52.45M. See Dermapharm Holding SE’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	€ 1.01B	€ 942.91M	€ 793.83M	€ 700.88M	€ 572.42M	€ 467.12M
Cost of Revenue	€ 358.42M	€ 322.22M	€ 330.35M	€ 317.16M	€ 274.97M	€ 245.64M
Gross Profit	€ 648.55M	€ 620.69M	€ 463.48M	€ 383.72M	€ 297.46M	€ 221.47M
Operating Expense	€ 391.73M	€ 333.65M	€ 318.21M	€ 263.98M	€ 189.42M	€ 130.66M
Operating Income	€ 256.82M	€ 287.04M	€ 145.27M	€ 119.74M	€ 108.04M	€ 90.81M
Net Non Operating Interest Income Expense	€ -7.97M	€ -5.81M	€ -10.07M	€ -8.34M	€ -5.07M	€ -6.08M
Other Income Expense	-	-	-	-	-	-
Pretax Income	€ 261.15M	€ 292.98M	€ 125.28M	€ 110.07M	€ 104.24M	€ 88.03M
Tax Provision	€ 86.22M	€ 84.07M	€ 39.36M	€ 32.25M	€ 29.01M	€ 10.29M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	€ 175.99M	€ 209.58M	€ 85.83M	€ 77.20M	€ 75.32M	€ 77.74M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	€ 4.88M	€ 9.74M	€ 8.08M	€ 6.31M	€ 4.54M
Total Expenses	€ 750.15M	€ 655.87M	€ 648.56M	€ 581.14M	€ 464.39M	€ 376.30M
Net Income From Continuing And Discontinued Operation	€ 175.99M	€ 209.58M	€ 85.83M	€ 77.20M	€ 75.32M	€ 77.74M
Normalized Income	€ 175.99M	€ 203.06M	€ 90.49M	€ 76.71M	€ 75.13M	€ 77.70M
Interest Expense	€ 9.56M	€ 8.84M	€ 9.36M	€ 10.89M	€ 6.83M	€ 7.21M
EBIT	€ 270.70M	€ 301.81M	€ 134.65M	€ 120.96M	€ 111.06M	€ 95.24M
EBITDA	€ 355.83M	€ 357.41M	€ 183.81M	€ 171.09M	€ 141.39M	€ 111.72M

Currency in EUR

Dermapharm Holding SE Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing